title: Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience.
abstract: We performed a Phase II trial to evaluate the activity and tolerability of docetaxel as a single agent in the treatment of advanced non-small cell lung cancer (NSCLC). Forty-four patients with metastatic and/or locally advanced NSCLC received i.v. docetaxel 100 mg/m2 every 3 weeks for a median of 4 (range 1-11) cycles. All patients received premedication with oral dexamethasone 8 mg twice daily for 5 days starting the day before chemotherapy. Seven partial responses were observed among 35 evaluable patients, and the overall response rate was 20% (95% CI 8-37). The median response duration was 5 months, median survival time was 10 months and the estimated 1-year survival rate was 42%. Treatment was generally well tolerated. Febrile neutropenia occurred in 10 patients (23%); neutropenic infection occurred in 4 patients, and led to 2 toxic deaths (both patients had borderline exclusion criteria). The corticosteroid premedication effectively reduced the overall incidence (34%) and severity (4% severe) of fluid retention, and delayed the median time to onset from cycle 4 to cycle 7. This study shows the promising efficacy of docetaxel as monotherapy in advanced NSCLC, and combination chemotherapy regimens incorporating docetaxel are now being evaluated in this clinical setting.
authors.affiliation: Centre Hospitalier de l'Université de Montréal, Quebec, Canada. jlatrei@cam.org
authors.forename: J
authors.initials: J
authors.lastname: Latreille
authors.forename: K A
authors.initials: KA
authors.lastname: Gelmon
authors.forename: V
authors.initials: V
authors.lastname: Hirsh
authors.forename: F
authors.initials: F
authors.lastname: Laberge
authors.forename: A W
authors.initials: AW
authors.lastname: Maksymiuk
authors.forename: F A
authors.initials: FA
authors.lastname: Shepherd
authors.forename: F
authors.initials: F
authors.lastname: Delorme
authors.forename: J
authors.initials: J
authors.lastname: Bérille
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002170:Canada; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D003907:Dexamethasone / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011292:Premedication; D016019:Survival Analysis; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005938:Glucocorticoids; D043823:Taxoids; D000077143:Docetaxel; D003907:Dexamethasone; D017239:Paclitaxel